Dr. Reddys launches Ezetimibe and Simvastatin tablets in US
DSIJ Intelligence / 27 Apr 2017
Dr. Reddy's Laboratories has launched Ezetimibe and Simvastatin Tablets, 10mg/10mg,10mg/20mg, 10mg/40mg, and 10mg/80mg, a therapeutic equivalent generic version of Vytorin tablets in the US market, approved by USFDA.
Dr. Reddy's Laboratories has launched Ezetimibe and Simvastatin Tablets, 10mg/10mg,10mg/20mg, 10mg/40mg, and 10mg/80mg, a therapeutic equivalent generic version of Vytorin tablets in the US market, approved by USFDA. The company is among the first companies to launch generic version product in US market.
The Vytorin brand had US sales of approximately USD 678 million (Rs 4348 crore) MAT for the most recent twelve months ended in February 2017 as per IMS Health. Vytorin is a registered trademark of MSD International GmbH.
On the financial front, Dr. Reddy's Laboratories’ revenue reduced 6.45 per cent to Rs 3723 crore in Q3FY17 as compared to same period in previous financial year. The company’s operating profit declined 12.19 per cent to Rs 865 crore in Q3FY17 on a yearly basis. Its net profit also decreased 15.95 per cent to Rs 492 crore in Q3FY17 as compared to same period in previous fiscal.
The stock price of Dr. Reddy’s Laboratories increased 0.61 per cent in early trade, and is trading at Rs 2600.9 on an intraday basis.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.